COVID-19 nasal vaccine may be registered in 2022
Illustrative photo from pixabay.com
Nasal vaccine against coronavirus, developed by scientists at the Gamaleya Center is to be put on clinical trials in late 2021 - early 2022, and registration of the drug - in 2022, said the director of the Center, Alexander Ginzburg, Tass.ru reports.
"The center is working in several directions at creating and improving vaccines against COVID-19. One direction is creation of a nasal form of the vaccine. Preclinical studies are currently underway. We plan clinical trials at the end of this - early next year, with its registration based on the study in 2022, "the scientist said.
According to Ginzburg, the advantage of this form of the vaccine is that there will be practically no side effects.